Definitive Contract 75F40125C00073
Award Date
9/15/25
Potential Completion Date
9/21/27
Potential Value
$661K
Federal Agency
Food and Drug Administration
Awardee
Simvantage GMBH
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Silver Spring, MD 20993, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract was awarded by the Department of Health and Human Services Food and Drug Administration (FDA) to the Universitat ST. Gallen, doing business as Hochschule FÜR Wirtschafts-, Rechts- UND Sozialwissenschaften (Hsg), an educational institution. The contract is a Firm Fixed Price definitive contract with a potential value of $764,418.19 and a completion date of September 29, 2023. The contract was awarded under the FDA's Broad Agency Announcement (BAA) for Advanced Regulatory...
This is a $165,457 firm-fixed price purchase order contract awarded by the Food and Drug Administration (FDA) to Global Life Sciences Solutions USA LLC, a for-profit limited liability company. The contract is for the delivery of mechanistic chromatography modeling software. This award is not associated with a set-aside program. Through this contract, the FDA is acquiring scientific software to support its biomedical research and laboratory operations. Global Life Sciences Solutions USA LLC is...
<p>This firm-fixed-price purchase order contract, valued at $155,000.00, was awarded by the Food and Drug Administration (FDA) to HK3 Lab S.R.L., a for-profit organization based in Italy. The contract is for an Artificial Intelligence Technical Expert, as described in the FDA's Sources Sought Notice FDA-SSN-1238254. The contract has an ultimate completion date of August 9, 2026. There is no set-aside designation mentioned. The contract was awarded on August 10, 2021.</p>
The Department of Health and Human Services Food and Drug Administration awarded a $371,836.31 purchase order contract to Siemens Government Technologies Inc., a subsidiary of Siemens Aktiengesellschaft, to provide software maintenance, licensing, and technical support for Siemens Smart Design and Manufacturing software products. The contract has a start date of June 30, 2022 and end date of January 31, 2025, and utilizes a firm fixed price contract type. Performance will take place in...
This is a $20,935.00 firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Siemens Process Systems Engineering Inc., a subsidiary of the German technology conglomerate Siemens Aktiengesellschaft. The contract is for flowsheet modeling and simulation software, with a period of performance from June 1, 2019 to May 31, 2021. This contract was not set aside for any specific business category. Siemens Aktiengesellschaft has a history of securing various federal...
The Department of Health and Human Services Food and Drug Administration awarded a definitive contract valued at $831,964 to Research Center Pharmaceutical Engineering GmbH. The firm fixed price contract is to provide services in support of the project titled "OCT for Real-Time Monitoring of Coating Process Dynamics & Product Quality" and will involve work by the prime contractor and its parent organization, Technische Universitaet Graz. The contract has a period of performance...
This is a $375,965.05 firm-fixed-price purchase order awarded by the Food and Drug Administration (FDA) to Simulations Plus Inc. for GastroPlus, DDDPlus, and MembraneePlus software licenses. The contract has an ultimate completion date of August 31, 2026 and does not have a set-aside designation. Simulations Plus is a for-profit company that specializes in developing pharmaceutical modeling and simulation software, including tools for physiologically-based pharmacokinetic (PBPK) modeling, drug...
This federal contract award, valued at $6,038,686.00, was issued by the Food and Drug Administration (FDA) to the Massachusetts Institute of Technology (MIT) to address the ongoing growth in continuous manufacturing within cell lines. The award is part of the FDA's Broad Agency Announcement (BAA) program, which funds extramural research and development to support regulatory science and innovation. The BAA solicitation did not have a set-aside designation. Through this contract, MIT will...
This is a $5,000,001.00 definitive contract awarded by the Food and Drug Administration (FDA) to the Massachusetts Institute of Technology (MIT) for "APPLICATION OF SMART DATA ANALYTICS FOR BIOMANUFACTURING." The contract has no set-aside designation and is a cost-type contract without fee. The contract was awarded under the FDA's Broad Agency Announcement for Advanced Regulatory Science, which solicits research and development proposals across various regulatory science areas to...
This is a $9,671,431.00 firm fixed-price definitive contract awarded by the Food and Drug Administration (FDA), a civilian agency, to Safe Health Systems, Inc., a self-certified small disadvantaged business. The contract is to stimulate innovation in clinical evaluations and personalized medicine to improve product development and patient outcomes. The contract has a period of performance through March 27, 2026 and does not utilize a set-aside. No additional details about larger contract...